Fresenius Medical Care AG & Co. KGaA (ETR: FME)‘s stock had its “add” rating reaffirmed by research analysts at AlphaValue in a report released on Thursday. They currently have a $78.57 (€60) target price on the stock.

Shares of Fresenius Medical Care AG & Co. KGaA traded down 1.30% during mid-day trading on Thursday, hitting €49.448. Fresenius Medical Care AG & Co. KGaA has a 52 week low of €50.573 and a 52 week high of €60.24. The stock’s 50-day moving average is currently €56.72.

FME has been the subject of a number of other recent research reports. Analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Friday, January 4th. They now have a $80.92 price target on the stock. Separately, analysts at JPMorgan Chase reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Thursday, January 3rd. They now have a $66.58 price target on the stock.

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.